Phaseline

Companies › Duke Street Bio

Duke Street Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DSB2455
PARP1 selective inhibitor
PARP1Phase 1Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)Aug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06458712DSB2455Phase 1Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)OncologyAug 2028

Targets

PARP1 (1)

Companies with the same targets

AstraZeneca Eikon Therapeutics Haisco Pharmaceutical Group Hangzhou SynRx Therapeutics Biomedical Technology Merck & Co. (MSD) Nerviano Medical Sciences Pfizer Johnson & Johnson (Janssen) Jiangsu Hansoh Pharmaceutical Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.